NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V.
Your view on NAMSW
Overview
What the company does, where it operates, and who runs it.
About NewAmsterdam Pharma Company N.V.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael Harvey Davidson Facp.
- Headquarters
- Gooimeer 2-35, Naarden, NH, NL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael Harvey Davidson Facp.
- Headquarters
- Gooimeer 2-35, Naarden, NH, NL
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases.
The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP).
Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for NewAmsterdam Pharma Company N.V., and the rating behind it. NAMSW last traded at $12.99; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for NewAmsterdam Pharma Company N.V.. Starting points for NewAmsterdam Pharma Company N.V.: EPS -$2.10, beta 0.11 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for NewAmsterdam Pharma Company N.V.. NewAmsterdam Pharma Company N.V. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for NewAmsterdam Pharma Company N.V.. Trailing twelve-month EPS for NewAmsterdam Pharma Company N.V. stands at -$2.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for NewAmsterdam Pharma Company N.V.. NewAmsterdam Pharma Company N.V. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
NewAmsterdam Pharma Company N.V. valued side by side against its closest peers. NewAmsterdam Pharma Company N.V. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold NewAmsterdam Pharma Company N.V., and how their positions are changing. At a $2.78B market value, institutional positions materially move NewAmsterdam Pharma Company N.V.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by NewAmsterdam Pharma Company N.V. executives and directors. Shares of NewAmsterdam Pharma Company N.V. have traded between $12.25 and $30.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming NewAmsterdam Pharma Company N.V.. NewAmsterdam Pharma Company N.V. is a $2.78B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming NewAmsterdam Pharma Company N.V.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for NewAmsterdam Pharma Company N.V.. Coverage tracks NewAmsterdam Pharma Company N.V. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.